arrow
S

Stephen D. Nimer

university of miami
H指数:80
被引数:2.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Real-world, multi-omics validation of the clinical relevance of molecular taxonomy for myelodysplastic syndromes (MDS)

多组学验证骨髓增生异常综合征(MDS)分子分类的临床相关性

2026-07-280
OAAI
Contemporary Approach to the Diagnosis and Classification of Myelodysplastic Neoplasms/SyndromesdRecommendations From the International Consortium for Myelodysplastic Neoplasms/Syndromes (MDS [icMDS])

骨髓增生异常肿瘤/综合征的诊断和分类的当代方法国际骨髓增生异常肿瘤/综合征联合会 (MDS [icMDS]) 的建议

2024-12-011
PRE
Altered RNA export by SF3B1 mutants confers sensitivity to nuclear export inhibition
LEUKEMIA
IF13.4
2024-07-130
OAAI
Toward a more patient-centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS)

在骨髓增生异常综合征/肿瘤 (MDS) 患者的临床试验中走向以患者为中心的药物开发过程: 国际MDS联合会 (icMDS) 的实际考虑

2024-05-210
OAAI
Genome-wide screening identifies Trim33 as an essential regulator of dendritic cell differentiation
2024-04-122
OA
Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS)

骨髓增生异常综合征/肿瘤 (MDS) 的分类,风险分层和反应评估: 代表国际MDS联合会 (icMDS) 的最新报告

2023-11-019
OAAI
An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS

推进骨髓增生异常综合征研究的议程: 第一届MDS国际研讨会的十大优先事项清单

2023-06-146
OAAI
Combined Use of RT-qPCR and NGS for Identification and Surveillance of SARS-CoV-2 Variants of Concern in Residual Clinical Laboratory Samples in Miami-Dade County, Florida
2023-02-214
OAAI
Oxidized mC modulates synthetic lethality to PARP inhibitors for the treatment of leukemia
2023-01-015
OAAI
Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes
LEUKEMIA
IF13.4
2022-10-2016
PRE